Fig. 6: Carbidopa inhibits proliferation of LNCaP cells via AHR. | Oncogenesis

Fig. 6: Carbidopa inhibits proliferation of LNCaP cells via AHR.

From: Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor

Fig. 6

a Colony formation assay: LNCaP cells were treated with or without Carbidopa (100 μM). Where indicated, AHR blocker CH223191 was present (10 μM). b TUNEL assay: LNCaP cells were treated with or without Carbidopa (100 μM). Where indicated, AHR blocker CH223191 was present (10 μM). Scale bars = 100 μm. c Quantitative analysis of TUNEL+ cells in at least three separate fields; data are given as means ± SEM. **p < 0.01 versus control. #p < 0.05 versus Carbidopa treatment. d Migration assay: LNCaP cells were treated with or without Carbidopa (100 μM). Where indicated, AHR blocker CH223191 was present (10 μM). Scale bars = 100 μm. e Quantification of the migration assay. Data are given as means ± SEM of three independent experiments. **p < 0.01 versus control. #p < 0.05 versus Carbidopa treatment.

Back to article page